REDHILL BIOPHAR/S (RDHL) Lowered to Hold at Zacks Investment Research

Share on StockTwits

REDHILL BIOPHAR/S (NASDAQ:RDHL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103). “

Other equities analysts also recently issued reports about the company. WBB Securities upgraded REDHILL BIOPHAR/S from a “speculative buy” rating to a “buy” rating and set a $17.00 price objective on the stock in a report on Tuesday, March 12th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of REDHILL BIOPHAR/S in a report on Wednesday, February 27th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. REDHILL BIOPHAR/S presently has a consensus rating of “Hold” and a consensus target price of $16.69.

REDHILL BIOPHAR/S stock opened at $8.60 on Friday. The firm has a market capitalization of $186.14 million, a price-to-earnings ratio of -5.06 and a beta of 1.75. REDHILL BIOPHAR/S has a fifty-two week low of $4.40 and a fifty-two week high of $11.49.

Institutional investors have recently added to or reduced their stakes in the company. Ibex Investors LLC raised its holdings in shares of REDHILL BIOPHAR/S by 78.2% in the 4th quarter. Ibex Investors LLC now owns 939,014 shares of the biotechnology company’s stock worth $5,212,000 after purchasing an additional 412,014 shares during the period. Disciplined Growth Investors Inc. MN acquired a new position in shares of REDHILL BIOPHAR/S during the 3rd quarter worth about $295,000. Creative Planning lifted its position in shares of REDHILL BIOPHAR/S by 73.9% during the 4th quarter. Creative Planning now owns 283,350 shares of the biotechnology company’s stock worth $1,573,000 after purchasing an additional 120,400 shares during the last quarter. CLARET ASSET MANAGEMENT Corp lifted its position in shares of REDHILL BIOPHAR/S by 42.1% during the 4th quarter. CLARET ASSET MANAGEMENT Corp now owns 67,522 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 20,000 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of REDHILL BIOPHAR/S by 61.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 73,878 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 28,102 shares during the last quarter. Institutional investors own 38.70% of the company’s stock.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Featured Story: Net Income

Get a free copy of the Zacks research report on REDHILL BIOPHAR/S (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.